Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.50

-1.3%

Jan 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	3/11/2002 4:21:30 PM
From: tuck	Read Replies (1) of 52153

More TA. Well not really, I'm referring to toxicogenomic analysis here. Aren't y'all relieved? Relief will be short lived, for the "Biotech Educator of the Year" (ha!) is getting on his soapbox. Some of you may be aware of my main -- indeed, only -- philosophical objection to biotech investing. That is the mass slaughter of experimental animals. Not going to start that discussion here, but it was for that reason I was hoping Xenogen would make a go of it (the IPO didn't make it last year). Another step towards effective, cruelty free, drug discovery comes to us via our new friend the microarray. Another nice thing about development incorporating toxicogenomics is the safety first approach, which seems to dovetail nicely with the FDA's attitude of late. Players include a couple of companies we know, DPII and AFFX. the-scientist.com So maybe someday soon we can be nicer to animals and satisfy the regulators. Thus killing two birds with one stone. Did I say that? No, I didn't say that. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next